Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial
Jennifer E Thorne, Elizabeth A Sugar, Janet T Holbrook, Alyce E Burke, Michael M Altaweel, Albert T Vitale, Nisha R Acharya, John H Kempen, Douglas A Jabs, Glenn J Jaffe, Christina F Bunn, LaToya Greene, Dilraj Grewal, Sean Grout, Michael Hughes, Ryan Imperio, Michael P Kelly, Brian Lutman, Paola Perez, Steven Yeh Show all
Ophthalmology | ELSEVIER SCIENCE INC | Published : 2019
Awarded by National Eye Institute, National Institutes of Health
Awarded by NATIONAL EYE INSTITUTE
This study is a multicenter clinic trial supported by collaborative agreements from the National Eye Institute, National Institutes of Health (D.A.J.: U10EY024526, J.T.H.: U10EY024527, M.M.A.: U10EY024531). Allergan (Irvine, CA) donated a limited supply of dexamethasone implants for participants who could not obtain them otherwise. A representative of the National Eye Institute participated in the oversight of the study and review of the manuscript but not directly in the study design, data collection, analysis, and interpretation of the data, or in the preparation of this manuscript.